title: Effect of abatacept on immunogenicity of vaccines in individuals with type 1 diabetes.
abstract: Abatacept delayed progression of type 1 diabetes (T1D) when administered soon after diagnosis. Its use in T1D is expanding to prevention trials and, therefore, it is important to fully characterize its immunosuppressive effect. We compared antibody responses to trivalent inactivated influenza vaccine (TIIV) administered during 2 consecutive seasons and to tetanus toxoid (TT) vaccine administered after 24 months of treatment in115 early onset T1D subjects randomly assigned to 24 months of abatacept (N=71) or placebo (N=34). Anti-influenza titers before TIIV were similar between the 2 treatment groups and both groups had significant increases after vaccination. Although the magnitude of antibody responses against some influenza serotypes was significantly lower (p<0.05) in abatacept compared with placebo recipients, no differences were observed in the proportion of subjects with protective titers against influenza after vaccination. The magnitude of antibody responses against TT also tended to be lower (p=0.06) in abatacept compared with placebo recipients, without affecting the proportion of subjects who achieved protective titers. We conclude that abatacept moderately decreases the magnitude of antibody responses to recall vaccination. Further studies are needed to assess its effect on primary immunization.
authors: Department of Pediatrics, University of Colorado Anschutz Medical Campus, Mail Stop 8604, 12700 East. 19th Avenue, Aurora, CO 80045, United States. Electronic address: Adriana.Weinberg@ucdenver.edu.
authors: Adriana
authors: A
authors: Weinberg
authors: David
authors: D
authors: Boulware
authors: Bonnie
authors: B
authors: Dighero
authors: Tihamer
authors: T
authors: Orban
mesh_terms: D000069594:Abatacept; D000293:Adolescent; D000328:Adult; D000907:Antibodies, Bacterial / Q000097:blood; D000914:Antibodies, Viral / Q000097:blood; D002648:Child; D003922:Diabetes Mellitus, Type 1 / Q000276:immunology*; D005260:Female; D006801:Humans; D018796:Immunoconjugates / Q000008:administration & dosage*; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D010919:Placebos / Q000008:administration & dosage; D013745:Tetanus Toxoid / Q000008:administration & dosage / Q000276:immunology*; D055815:Young Adult
chemical_list: D000907:Antibodies, Bacterial; D000914:Antibodies, Viral; D018796:Immunoconjugates; D007166:Immunosuppressive Agents; D007252:Influenza Vaccines; D010919:Placebos; D013745:Tetanus Toxoid; D000069594:Abatacept
keywords: Abatacept; Influenza vaccine; Tetanus vaccine; Type 1 diabetes mellitus
references: Curr Opin Organ Transplant. 2012 Aug;17(4):368-75
references: 22790071
references: J Infect Dis. 2012 Aug 1;206(3):421-30
references: 22615311
references: Ann Rheum Dis. 2011 Oct;70(10):1826-30
references: 21893583
references: N Engl J Med. 2009 Nov 26;361(22):2143-52
references: 19940299
references: Rheumatology (Oxford). 2012 Apr;51(4):695-700
references: 22171015
references: Arthritis Care Res (Hoboken). 2013 Mar;65(3):476-80
references: 22949223
references: J Clin Invest. 1999 May;103(9):1243-52
references: 10225967
references: J Immunol. 2011 Aug 15;187(4):1998-2005
references: 21775681
references: Lancet. 2011 Jul 30;378(9789):412-9
references: 21719096
references: Arthritis Res Ther. 2007;9(2):R38
references: 17425783
references: PLoS One. 2012;7(9):e45185
references: 23024807